Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
7.23M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
2.37M
-
Shares change
-
-48K
-
Total reported value, excl. options
-
$31.5M
-
Value change
-
-$411K
-
Number of buys
-
19
-
Number of sells
-
-13
-
Price
-
$13.31
Significant Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q4 2024
43 filings reported holding ATRA - Atara Biotherapeutics, Inc. - Common Stock as of Q4 2024.
Atara Biotherapeutics, Inc. - Common Stock (ATRA) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.37M shares
of 7.23M outstanding shares and own 32.74% of the company stock.
Largest 10 shareholders include EcoR1 Capital, LLC (532K shares), Redmile Group, LLC (442K shares), CITADEL ADVISORS LLC (267K shares), BANK OF AMERICA CORP /DE/ (205K shares), VANGUARD GROUP INC (179K shares), Vestal Point Capital, LP (125K shares), ACADIAN ASSET MANAGEMENT LLC (124K shares), TANG CAPITAL MANAGEMENT LLC (75.2K shares), RENAISSANCE TECHNOLOGIES LLC (67.1K shares), and BlackRock, Inc. (60.8K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.